Discovery of the biosynthetic pathway of a plant metabolite lays the groundwork for its use as an anti-diabetes drug.
Montbretin A (MbA), a natural compound with great potential for the treatment of type-2 diabetes, was discovered in the ornamental plant montbretia ten years ago, but it can’t be produced on a large scale until its biosynthesis is understood. Canadian scientists discovered genes and enzymes responsible for MbA biosynthesis and demonstrated the potential for metabolic engineering of wild tobacco to produce this promising drug candidate.
Roughly half of the western medicines used today were derived from naturally occurring plant metabolites. Plants produce over 200,000 of these specialized metabolites, but identifying medicinally useful ones is challenging, and obtaining sufficient quantities for human use poses an even greater challenge. Type-2 diabetes, a disease characterized by elevated blood glucose levels due to the body’s inefficient use of insulin, affects over 320 million people worldwide. Drugs that are commonly used to treat type-2 diabetes reduce blood glucose levels by inhibiting the activities of two enzymes: HPA (pancreatic alpha-amylase), which cleaves complex starches into strings of sugar molecules called oligosaccharides and alpha-glucosidases, which convert oligosaccharides into glucose in the gut. Unfortunately, the inhibition of alpha-glucosidases causes some undigested oligosaccharides to move into the lower bowel, leading to flatulence and diarrhea.
Ten years ago, in an effort to produce a diabetes drug that specifically inhibits HPA activity without having nasty side effects, scientists screened 30,000 extracts derived from plants and other organisms and found a single compound that fit the bill: montbretin A (MbA) from the bulb-like underground corms of the ornamental plant montbretia (Crocosmia x crocosmiiflora) (see figure). Unfortunately, MbA can’t be produced in large quantities without understanding the biochemical pathway and genes involved in its biosynthesis, a difficult task considering the diversity and complexity of plant metabolic pathways.
Scientists from the University of British Columbia and the Canadian Glycomics Network analyzed this crucial pathway, as discussed in this month’s issue of The Plant Cell. The scientists discovered the first three intermediate metabolites in the MbA biosynthesis pathway, including a product called mini-MbA, which also strongly inhibits HPA activity, as well as the four enzymes involved in mini-MbA production. Importantly, when they cloned the genes for these enzymes and used them to genetically transform wild tobacco, they successfully obtained mini-MbA.
According to lead scientist, Dr. Joerg Bohlmann of the University of British Columbia, Vancouver BC, “This is a fascinating example of the largely undiscovered potential of plant specialized metabolism that may lead to new treatments for the improvement of human health”. Montbretia, a popular summer garden plant.
Jennifer Lockhart, PhD
Science Editor, The Plant Cell
The research was supported with funds from the GlycoNet, the Natural Sciences and Engineering Research Council of Canada (NSERC), and the Canadian Institutes for Health Research, as well as the Alexander von Humboldt Foundation through a Feodor Lynen Research Fellowship, the UBC Genome Science and Technology (GSAT) Graduate Program, and an NSERC Canada Graduate Scholarship-Master’s, and the British Columbia Epilepsy Society.
Full citation: Irmisch, S., Jo, S., Roach, C.R., Jancsik, S., Yuen, M.M.S., Madilao, L.L, O’Neil-Johnson, M., Williams, R., Withers, S.G., and Bohlmann, J. (2018). Discovery of UDP Glycosyltransferases and BAHDAcyltransferases Involved in the Biosynthesis of the Anti-Diabetic Plant Metabolite Montbretin. Plant Cell 10.1105/tpc.18.00406. Advance Publication: July 29, 2018 http://www.plantcell.org/content/early/…
About the researchers: To arrange an interview with Dr. Joerg Bohlmann of the University of British Columbia, please contact firstname.lastname@example.org.
About The Plant Cell
Published monthly by ASPB, The Plant Cell (http://www.plantcell.org/) is the highest-ranking primary research journal in plant biology. The Plant Cell publishes novel research in plant biology, especially in the areas of cellular biology, molecular biology, genetics, development, and evolution. The primary criteria for publication are that the article provides new insight that is of broad interest to plant biologists, not only to specialists, and that the presentation of results is appropriate for a wide audience.
ASPB is a professional scientific society, headquartered in Rockville, Maryland, devoted to the advancement of the plant sciences worldwide. With a membership of almost 5000 plant scientists from throughout the United States and more than 50 other nations, the Society publishes two of the most widely cited plant science journals: The Plant Cell and Plant Physiology.
For more information about ASPB, please visit http://www.aspb.org/ Also, follow ASPB on Facebook at facebook.com/myASPB and on Twitter @ASPB. Figure credit: Seohyun (Jenny) Jo, University of British Columbia.
Restrictions: Use for non-commercial, educational purposes is granted without written permission. Please include a citation and acknowledge ASPB as the copyright holder. For all other uses, contact email@example.com.
Key words: Medicinal plants, specialized metabolites, Type-2 diabetes, montbretia, enzyme, plant science